Latexin Is Down-Regulated in Hematopoietic Malignancies and Restoration of Expression Inhibits Lymphoma Growth

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Liu, Yi ^a   Howard, Dianna ^a   Rector, Kyle ^a   Swiderski, Carol ^a   Brandon, Jason ^a   Schook, Lawrence ^b   Mehta, Jayesh ^c   Bryson, J Scott ^a   Bondada, Subbarao ^a   Liang, Ying ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; LATEXIN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN PIM 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD; BONE MARROW; CANCER INHIBITION; CD34 SELECTION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LXN GENE; LYMPHOMA CELL; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN METHYLATION; RETROVIRUS; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ANIMALS; ANTIGENS; ANTIGENS, CD34; APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; INDICATORS AND REAGENTS; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC;

MUS;

EID: 84866931897     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044979     Document Type: Article

References (38)

1. Dick JE, Lapidot T, (2005) Biology of normal and acute myeloid leukemia stem cells. Int J Hematol 82: 389-396.
2. Marx J, (2007) Molecular biology. Cancer's perpetual source? Science 317: 1029-1031.
3. Huntly BJ, Gilliland DG, (2005) Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5: 311-321.
4. Liang Y, Jansen M, Aronow B, Geiger H, Van Zant G, (2007) The quantitative trait gene latexin influences the size of the hematopoietic stem cell population in mice. Nat Genet 39: 178-188.
5. Arimatsu Y, (1994) Latexin: a molecular marker for regional specification in the neocortex. Neurosci Res 20: 131-135.
6. Hatanaka Y, Uratani Y, Takiguchi-Hayashi K, Omori A, Sato K, et al. (1994) Intracortical regionality represented by specific transcription for a novel protein, latexin. Eur J Neurosci 6: 973-982.
7. Arimatsu Y, Ishida M, Takiguchi-Hayashi K, Uratani Y, (1999) Cerebral cortical specification by early potential restriction of progenitor cells and later phenotype control of postmitotic neurons. Development 126: 629-638.
8. Arimatsu Y, Kojima M, Ishida M, (1999) Area- and lamina-specific organization of a neuronal subpopulation defined by expression of latexin in the rat cerebral cortex. Neuroscience 88: 93-105.
9. Arimatsu Y, Ishida M, Kaneko T, Ichinose S, Omori A, (2003) Organization and development of corticocortical associative neurons expressing the orphan nuclear receptor Nurr1. J Comp Neurol 466: 180-196.
10. Jin M, Ishida M, Katoh-Fukui Y, Tsuchiya R, Higashinakagawa T, et al. (2006) Reduced pain sensitivity in mice lacking latexin, an inhibitor of metallocarboxypeptidases. Brain Res 1075: 117-121.
11. Aagaard A, Listwan P, Cowieson N, Huber T, Ravasi T, et al. (2005) An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1. Structure (Camb) 13: 309-317.
12. Uratani Y, Takiguchi-Hayashi K, Miyasaka N, Sato M, Jin M, et al. (2000) Latexin, a carboxypeptidase A inhibitor, is expressed in rat peritoneal mast cells and is associated with granular structures distinct from secretory granules and lysosomes. Biochem J 346 Pt 3: 817-826.
13. Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, et al. (2004) Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res 64: 2411-2417.
14. Jing C, El-Ghany MA, Beesley C, Foster CS, Rudland PS, et al. (2002) Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst 94: 482-490.
15. Kwong J, Lo KW, Chow LS, Chan FL, To KF, et al. (2005) Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. Int J Cancer 113: 386-392.
16. Zhang J, Liu L, Pfeifer GP, (2004) Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene. Oncogene 23: 2241-2249.
17. Termini L, Boccardo E, Esteves GH, Hirata R Jr, Martins WK, et al. (2008) Characterization of global transcription profile of normal and HPV-immortalized keratinocytes and their response to TNF treatment. BMC Med Genomics 1: 29.
18. Li Y, Basang Z, Ding H, Lu Z, Ning T, et al. (2011) Latexin expression is downregulated in human gastric carcinomas and exhibits tumor suppressor potential. BMC cancer 11: 121.
19. Mitsunaga K, Kikuchi J, Wada T, Furukawa Y, (2012) Latexin regulates the abundance of multiple cellular proteins in hematopoietic stem cells. Journal of cellular physiology 227: 1138-1147.
20. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, et al. (2006) Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer research 66: 11187-11193.
21. Feinberg AP, Ohlsson R, Henikoff S, (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
22. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, et al. (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 102: 10604-10609.
23. Fraga MF, Esteller M, (2007) Epigenetics and aging: the targets and the marks. Trends Genet 23: 413-418.
24. Fraga MF, Agrelo R, Esteller M, (2007) Cross-talk between aging and cancer: the epigenetic language. Ann N Y Acad Sci 1100: 60-74.
25. Shames DS, Minna JD, Gazdar AF, (2007) DNA methylation in health, disease, and cancer. Curr Mol Med 7: 85-102.
26. Oakley EJ, Van Zant G, (2007) Unraveling the complex regulation of stem cells: implications for aging and cancer. Leukemia 21: 612-621.
27. Toyota M, Issa JP, (2005) Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32: 521-530.
28. Sahab ZJ, Hall MD, Me Sung Y, Dakshanamurthy S, Ji Y, et al. (2011) Tumor suppressor RARRES1 interacts with cytoplasmic carboxypeptidase AGBL2 to regulate the alpha-tubulin tyrosination cycle. Cancer research 71: 1219-1228.
29. Blanco-Aparicio C, Molina MA, Fernandez-Salas E, Frazier ML, Mas JM, et al. (1998) Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth. J Biol Chem 273: 12370-12377.
30. Dykstra B, Olthof S, Schreuder J, Ritsema M, de Haan G, (2011) Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. The Journal of experimental medicine 208: 2691-2703.
31. Greaves M, Maley CC, (2012) Clonal evolution in cancer. Nature 481: 306-313.
32. Kelly PN, Strasser A, (2011) The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell death and differentiation 18: 1414-1424.
33. Yan B, Zemskova M, Holder S, Chin V, Kraft A, et al. (2003) The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. The Journal of biological chemistry 278: 45358-45367.
34. Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, et al. (2006) Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC cell biology 7: 1.
35. Gomez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, Gonzalez-Menchen A, et al. (2011) PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood 118: 5517-5527.
36. Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, et al. (2010) A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 115: 824-833.
37. Agrawal-Singh S, Koschmieder S, Gelsing S, Stocking C, Stehling M, et al. (2010) Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model. Blood 115: 4507-4516.
38. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, et al. (2005) c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106: 1382-1391.